<DOC>
	<DOCNO>NCT00005887</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs RSR13 may make tumor cell sensitive radiation therapy . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy brain without RSR13 treat patient brain metastasis .</brief_summary>
	<brief_title>Radiation Therapy With Without RSR13 Treating Patients With Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Compare median survival time patient brain metastasis receive treatment whole brain radiotherapy without RSR13 . - Compare response rate treatment regimens patient . - Compare time progression receive treatment regimens patient . - Compare quality life patient receive treatment regimen . - Compare cause death ( neurologic v nonneurologic death ) patient receive treatment regimen . - Determine safety RSR13 patient . - Assess pharmacokinetics RSR13 patient . OUTLINE : This randomize , open label , comparative , multicenter study . Patients stratify accord Radiation Therapy Oncology Group RPA Class ( I vs II ) . Patients stratify within RPA class II stratum accord site primary cancer ( non-small cell lung cancer v breast v ) . Patients randomize one two treatment arm . - Arm I : Patients receive whole brain radiotherapy 5 day week two week conjunction supplemental oxygen breathing . - Arm II : Patients receive RSR13 IV 30 minute follow whole brain radiotherapy supplemental oxygen breathe arm I . Quality life assess first last day radiotherapy , 1 month , 3 month , every 3 month disease progression . Patients follow 1 month , 3 month , every 3 month disease progression , survival . PROJECTED ACCRUAL : A maximum 408 ( 204 per treatment arm ) patient accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Efaproxiral</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Radiographically , histologically , cytologically confirm brain metastasis histologically cytologically confirm primary malignancy except follow : Small cell lung cancer , germ cell tumor , lymphomas No leptomeningeal metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Hemoglobin least 10 g/dL WBC least 2,000/mm3 Platelet count least 75,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL ALT AST great 3 time upper limit normal Renal : Creatinine great 2.0 mg/dL Pulmonary : Forced vital capacity force expiratory volume least 50 % normal patient significant intrathoracic tumor involvement , chronic obstructive pulmonary disease , interstitial lung disease , pulmonary embolism Resting exercise oxygen saturation least 90 % room air Other : No concurrent active malignancy second histologic site Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy immunotherapy brain metastasis At least 28 day since prior investigational biologic therapy Chemotherapy : No prior chemotherapy brain metastases No chemotherapy brain metastasis least one month follow radiation therapy At least 7 day since prior chemotherapy primary tumor extracranial metastases No planned chemotherapy radiation therapy Endocrine therapy : No prior hormonal therapy brain metastasis Prior concurrent corticosteroid therapy allow Radiotherapy : No prior whole brain radiotherapy brain metastases No prior stereotactic radiosurgery brain metastasis Surgery : Prior surgery allow brain metastasis least one measurable lesion remain Other : At least 28 day since prior investigational drug device No prior RSR13</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>tumor metastatic brain</keyword>
</DOC>